Natalie Prow

Research Fellow in Vaccinology

University of York, United Kingdom (UK)

Email: natalie.prow@york.ac.uk

VALIDATE Role:

Network Associate

Research Keywords:

Cutaneous Leishmania Vaccine Development, Skin Delivery

Biography:

My research interests developing low cost improved vaccine outcomes for the neglected tropical diseases using skin delivery. I have generated preliminary data to demonstrate that skin delivery is capable of inducing immunity comparable to traditional vaccine delivery, designed a novel vaccine for cutaneous leishmaniasis and developing platform immunological assays to assess vaccine candidates for generation of immunogenicity and assessment of key immune cells within the skin. While these assays were designed to evaluate Leishmania vaccines, the assays are versatile and can be easily adapted to any vaccine or any skin condition. I am currently in the process of understanding mechanisms leading to the induction of vaccine immunity and protection. I am also interested in natural viral symbionts of parasite and how these viruses may influence vaccine efficacy.

Related Websites:

Hull York Medical School

Key Publications:

Prow NA, et al., A vaccinia-based single vector construct multi-pathogen vaccine protects against both Zika and chikungunya viruses. Nature Communications; 2018. 9(1):1230. doi: 10.1038/s41467-018-03662-6.
Prow, N.A., Liu, L., McCarthy, M.K. et al. The vaccinia virus based Sementis Copenhagen Vector vaccine against Zika and chikungunya is immunogenic in non-human primates. npj Vaccines 5, 44; 2020. https://doi.org/10.1038/s41541-020-0191-8
Eldi P*, Cooper TH*, Prow NA*, Liu L, Heinemann GK, Zhang VJ, Trinidad AD, Guzman-Genuino RM, Wulff P, Hobbs LM, Diener KR, Hayball JD. The vaccinia-based Sementis Copenhagen Vector coronavirus disease 2019 vaccine induces broad and durable cellular and humoral immune responses. Immunol Cell Biol. 2022. 100(4): 250-266. doi: 10.1111/imcb.12539; *equal contributors